- AstraZeneca has reported disappointing results from a trial of its lung cancer drug, Imfinzi.

AstraZeneca and MedImmune, its global biologics research and development arm, said the combination of Imfinzi and tremelimumab did not meet the primary endpoint of improving progression-free survival versus platinum-based standard-of-care chemotherapy in previously-untreated patients with metastatic (Stage IV) 1st-line non-small cell lung cancer.

AstraZeneca said that as a secondary endpoint, although not formally tested, Imfinzi monotherapy would not have met a pre-specified threshold of PFS benefit over SoC in this disease setting.

AstraZeneca said the phase III MYSTIC trial would continue to assess two additional primary endpoints of overall survival (OS) for Imfinzi monotherapy and OS for the Imfinzi plus tremelimumab combination.

It said final OS data from both primary endpoints was expected during the first half of 2018. Executive vice-president, global medicines development and chief medical officer Sean Bohen said: "While the results from the MYSTIC trial for progression free survival in first-line Stage IV non-small cell lung cancer compared with standard of care are disappointing, the trial was designed to assess overall survival and we look forward to evaluating the remaining primary endpoints of overall survival for both mono- and combination therapy."

At 9:33am: [LON:AZN] AstraZeneca PLC share price was -812p at 4301p

Story provided by